Applications of Boc-(S)-3-Amino-4-(3,4-Dichloro-Phenyl)-Butyric Acid in Industrial Manufacturing

Boc-(S)-3-Amino-4-(3,4-Dichloro-Phenyl)-Butyric Acid acts as a critical protected amino acid intermediate within regulated fine chemical and pharmaceutical synthesis. We supply this material directly to regulated manufacturers operating in several advanced sectors. The following sections highlight proven downstream application tracks, technical entry points, regulatory frameworks, and representative finished goods in which our product plays an essential role.

1. Peptide API Synthesis for CNS Drug Development

This material is a cornerstone for synthesizing protected peptide fragments targeting central nervous system (CNS) therapies, where precise chiral control and electron-rich aromatic structures are necessary for receptor specificity and metabolic stability. Research and production facilities employ this intermediate in solid-phase peptide synthesis (SPPS) using Fmoc/tBu or Boc strategy to introduce non-natural amino acid residues. Regulatory agencies strictly monitor the synthesis process, especially documentation for trace impurities and product consistency due to patient safety concerns.

Industry compliance standards

• International Council for Harmonisation (ICH Q7) GMP guidance
• United States Pharmacopeia (USP) <1058>, <621>
• EU EMA Guidelines for APIs used in human medicinal products
• FDA DMF (Drug Master File) registration

Typical usage ratio

• 0.5–5 mol% relative to peptide elongation step; adjusted to peptide chain length and side-chain diversity requirements

Downstream process integration

• Added as a protected amino acid building block during stepwise peptide chain assembly on resin in SPPS reactors, introduced via automated dosing at the designated sequence position, followed by on-resin deprotection and downstream cleavage

Final product types

• Investigational new drug (IND) peptides for CNS disorders
• Commercial CNS peptide APIs
• Peptidomimetic reference standards
• Preclinical CNS peptide libraries

2. Chiral Intermediate in Non-Opioid Analgesic Synthesis

The material’s protected form allows integration into multi-step synthetic routes for small-molecule analgesics. Its stereochemistry is critical in constructing advanced chiral centers that influence binding to specific CNS targets, reducing off-target effects. This step usually involves amide coupling followed by global deprotection before final cyclization or side-chain addition. Regulatory filings and process validation require detailed route documentation, impurity profiling, and batch traceability for each production lot.

Industry compliance standards

• GMP per 21 CFR Part 210, 211
• ICH Q3A/B Residual Solvents and Impurity Guidelines
• Japanese Pharmacopoeia (JP) synthetic intermediate controls
• Change control and deviation recording as per ICH Q10

Typical usage ratio

• 1.5–4 mol% depending on desired chiral catalyst loading and overall yield optimisation

Downstream process integration

• Undergoes coupling with activated carboxylic derivatives in batch or flow reactors at the enantiopure intermediate stage, typically followed by solvent switch and deprotection for subsequent steps

Final product types

• Non-opioid analgesic APIs
• Advanced analgesic intermediates for scale-up studies
• Reference standards for regulatory submissions
• Route scouting intermediates for SAR studies

3. Building Block in Specialty Agrochemical Active Production

The protected amino acid is utilized by specialized agrochemical producers as a key segment for constructing herbicidal and insecticidal active compounds where selective aromatic substitution and chiral centers improve biological activity. Agrochemical GMPs and environmental safety guidelines require stringent documentation at each synthetic stage, particularly in managing dichloro-aromatic waste. The intermediate enters nucleophilic or reductive amination steps under monitored conditions to avoid racemization or functional group degradation.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) for industrial synthesis
• FAO/WHO pesticide technical material standards
• ISO 9001:2015 quality management system
• REACH registration for bulk shipments within the EU

Typical usage ratio

• 0.8–3.2 mol%, optimized for activity screening and downstream structure-activity relationship tests

Downstream process integration

• Integrated into in-situ coupling with haloarene derivatives under Schotten-Baumann or carbodiimide-mediated conditions, followed by sequential deprotection and formylation/cyclization as required by product structure

Final product types

• Agrochemical actives for selective herbicides
• Pre-commercial pesticide candidates
• Crude actives for biological testing
• Advanced intermediates for EPA registration batches

4. Protected Precursor for Veterinary Drug Formulation

Veterinary pharmaceutical companies incorporate our product as a key protected amino acid during synthesis of chiral veterinary APIs, particularly for livestock and companion animal indications. Regulatory demands require strict segregation of production lines, trace heavy metal and solvent residue testing, and batch documentation for veterinary health authorities. The protected intermediate is introduced early in multi-step syntheses, enabling flexible late-stage functionalization without side reactions, with all waste and byproduct streams documented for compliance.

Industry compliance standards

• VICH GL3: Good Manufacturing Practice for APIs for veterinary use
• US FDA CVM guidance for animal drugs
• EU Regulation (EC) No 470/2009 on residue limits
• China Veterinary Pharmacopoeia requirements

Typical usage ratio

• 1–6 mol% as determined by species- and product-specific formulation needs and target chiral purity

Downstream process integration

• Introduced into initial multi-step synthesis as a protected chiral amino acid, with strategic deprotection prior to final purification, enabling subsequent salt formation and direct inclusion in drug substance manufacturing

Final product types

• Veterinary active pharmaceutical ingredients (APIs)
• Chiral veterinary prodrugs
• Bulk intermediates for contract veterinary synthesis
• Finished multi-species veterinary drugs

5. Research-Grade Reference Standard for Analytical Laboratories

Accredited analytical labs require this protected amino acid as a research-grade reference standard for HPLC, LC-MS, and NMR characterization of process impurities, related substances, and raw material qualification in fine chemical and API suites. Supply for this segment must comply with ISO documentation, reference standard identity confirmation, and metrological traceability. Labs use the material both as a calibrant and spiking standard, supporting process validation and customer regulatory submissions.

Industry compliance standards

• ISO/IEC 17025 accreditation requirements
• USP General Chapter 1225, "Validation of Compendial Procedures"
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria
• Chinese Pharmacopoeia (ChP) reference substance management

Typical usage ratio

• 0.01–0.1 wt% as analytical standard, adjusted for instrument calibration protocol

Downstream process integration

• Dissolved directly into analytical grade solvents for reference standard preparation, used in identification, method validation, and process control checks, with protocols for recovery and trace impurity quantification

Final product types

• Calibrated reference materials for drug synthesis analysis
• Analytical test kits for identity and purity determination
• Process control standards for QC departments
• Qualification standards for regulatory method filing